System and method for improving the drug therapy management
Inventors
Mougiakakou, Stavroula • Sun, Qingnan • JANKOVIC, Marko • Piveteau, Laurent-Dominique • Proennecke, Stephan • BUDZINSKI, João
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11430557-B2
Publication Date
2022-08-30
Expiration Date
Abstract
An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.
Core Innovation
The invention relates to diabetes management for adapting insulin therapy by retrieving, from a memory device, at least two measurements of blood glucose of a patient performed by a Self-Monitoring Blood Glucose device over a first time-period. The method also retrieves, from the memory device, at least one of a medication delivery parameter executed over the first time-period and data associated to the Carbohydrate to Insulin Ratio (CIR) information of the patient, and a processor unit determines a therapy modification that comprises at least one of a modification to the basal rate and a modification to the CIR for a subsequent time-period.
The therapy modification is configured to be used for a subsequent time period by a delivery device, and the method further comprises at least one of suggesting the therapy modification to the patient and delivering an insulin amount by taking into account the therapy modification for the subsequent time-period. The invention also includes determining therapy modifications based on a tuning module that performs retrieval from memory and determination based on at least part of the retrieved data.
The invention further provides device-independent operation and closed-loop monitoring concepts. A non-transitory computer readable medium enables determining a medication delivery parameter and/or CIR independently of the type of glucose monitoring device used between a Self Monitoring Blood Glucose device and a Continuous Glucose Monitoring device (CGM). For monitoring a closed loop device, acceptable data are determined comprising at least one of a basal rate and/or a CIR for a subsequent time period, and the acceptable data are compared to data computed by the closed loop device or to the medication delivery parameter (or CIR) intended for a subsequent time period, followed by alerting the patient or a user or suggesting another medication delivery parameter in compliance with the acceptable range.
Claims Coverage
The document includes four independent claims covering a method for adapting therapy with limited glucose measurements and basal-rate/CIR updates, a diabetes management system implementing the same concepts using a Self-Monitoring Blood Glucose device, a non-transitory computer readable medium that enables device-independent determination between SMBG and CGM, and a method for monitoring a closed-loop device using acceptable basal/CIR ranges with alerting or suggestions. Across these independent claims, the inventive features consistently focus on retrieving glucose and medication/CIR data from memory over a first time-period, determining basal rate and/or CIR modifications for a subsequent time-period, and using the modification for insulin delivery or closed-loop comparison.
Therapy adaptation using limited glucose measurements and retrieved medication/CIR data
Retrieving from a memory device at least two measurements of blood glucose of a patient performed by a Self-Monitoring Blood Glucose device over a first time-period; retrieving from a memory device at least one of a medication delivery parameter executed over the first time-period, including at least one of a basal rate and a bolus, and data associated to the Carbohydrate to Insulin Ratio (CIR) information of the patient; determining, by a processor unit, a therapy modification by taking into account the at least two measurements and the retrieved data, wherein the therapy modification comprises at least one of a modification to the basal rate and a modification to the CIR that will be used for a subsequent time-period; and at least one of suggesting to the patient the therapy modification and delivering an insulin amount by taking into account the therapy modification for a subsequent time-period.
Diabetes management system with SMBG-provided glucose data for basal-rate/CIR therapy modification
An input device configured for receiving glucose data relating to a glucose level of the patient; a delivery device configured for delivering insulin to the patient according to a medication delivery parameter including at least one of a basal rate and a bolus; a memory device configured to store at least one glucose data and at least one of the medication delivery parameter and a Carbohydrate to Insulin Ratio (CIR) information of the patient; and a tuning module comprising a processor and computer-executable instructions that perform retrieval from the memory device at least two glucose data over a first time-period, retrieval of at least one of the medication delivery parameter executed over the first time-period and the CIR, and determination based on at least a part of the retrieved data of a therapy modification comprising a modification of at least one of the basal rate and the CIR, wherein the therapy modification is configured to be used for a subsequent time period by the delivery device, and wherein the glucose data are provided by a Self-Monitoring Blood Glucose device.
Device-independent determination of medication delivery parameter/CIR between SMBG and CGM
A non-transitory computer readable medium having a computer program logic for enabling at least one processor in a computer system to perform a method to determine a medication delivery parameter and/or Carbohydrate to Insulin Ratio (CIR) information independently of the type of glucose monitoring device used between a Self Monitoring Blood Glucose device and a Continuous Glucose Monitoring device (CGM), the method comprising obtaining at least two measurements of glucose level of the patient performed over a first time-period; obtaining at least one of a medication delivery parameter executed over the first time-period, including at least one of a basal rate and a bolus, and/or a CIR of the patient, and determining a medication delivery parameter and/or a CIR which may be used for a subsequent time period by taking into account the obtained data.
Closed-loop monitoring using acceptable basal/CIR data with comparison, alerting, and compliant suggestion
A method adapted for monitoring a closed loop device, the method comprising obtaining at least two measurements of glucose level of the patient performed over a first time-period; obtaining at least one of a medication delivery parameter executed over the first time-period including at least one of a basal rate and a bolus and/or a CIR which may be used for calculating a bolus during the first time-period; determining a set of acceptable data comprising at least one of a basal rate and/or a CIR which may be used for a subsequent time period, based on the obtained data; comparing the set of acceptable data to the data computed by the closed loop device for a subsequent time-period or comparing the set of acceptable data to the medication delivery parameter (or CIR) intended to be used for a subsequent time-period; wherein the method further comprises alerting the patient or a user and/or suggesting another medication delivery parameter in compliance with the said acceptable range.
Across the independent claims, the core coverage is the retrieval of at least two glucose measurements over a first time-period from an SMBG device, retrieval of medication delivery parameter and/or CIR information from memory, determination of a therapy modification that includes basal-rate and/or CIR updates for a subsequent time-period, and using the modification for insulin delivery. Additional claim coverage includes determining basal/CIR changes independently of glucose monitoring device type between SMBG and CGM, and monitoring closed-loop computations by comparing computed values to an acceptable basal/CIR set with alerting or compliant suggestions.
Stated Advantages
Independence from the type of glucose monitoring device used between a Self Monitoring Blood Glucose device and a Continuous Glucose Monitoring device (CGM).
Capability to operate with glucose data provided by a Self-Monitoring Blood Glucose device for determining basal-rate and/or CIR therapy modifications.
Closed-loop monitoring by computing an acceptable range of basal rate and/or CIR and alerting the patient/user or suggesting a medication delivery parameter when deviations occur.
Documented Applications
No documented applications found
Interested in licensing this patent?